Trade

with

Immunomedics Inc
(NASDAQ: IMMU)
AdChoices
3.78
+0.02
+0.53%
After Hours :
3.78
0.00
0.00%

Open

3.77

Previous Close

3.76

Volume (Avg)

366.04k (608.87k)

Day's Range

3.72-3.83

52Wk Range

3.04-6.17

Market Cap.

351.97M

Dividend Rate ( Yield )

-

Beta

0.87

Shares Outstanding

93.13M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 9.04M

    • Net Income

    • -35.43M

    • Market Cap.

    • 351.97M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -391.81

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.87

    • Forward P/E

    • -6.52

    • Price/Sales

    • 35.34

    • Price/Book Value

    • 8.94

    • Price/Cash flow

    • -9.99

      • EBITDA

      • -35.01M

      • Return on Capital %

      • -74.76

      • Return on Equity %

      • -92.84

      • Return on Assets %

      • -74.76

      • Book Value/Share

      • 0.42

      • Shares Outstanding

      • 93.13M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 8.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.58

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -12.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -21.34

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -289.40

            • 82.75

            • Pre-Tax Margin

            • -392.89

            • 39.38

            • Net Profit Margin

            • -391.81

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 19.40

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -136.10

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -135.20

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 6.90

              • 2.92

              • Quick Ratio

              • 6.60

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.19

              • 2.21

              • Book Value/Share

              • 0.42

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -8.72

                • 217.39

                • P/E Ratio 5-Year High

                • -17.56

                • 634.30

                • P/E Ratio 5-Year Low

                • -5.04

                • 124.82

                • Price/Sales Ratio

                • 34.13

                • 9.52

                • Price/Book Value

                • 8.64

                • 8.61

                • Price/Cash Flow Ratio

                • -9.99

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -92.84

                    (0.80)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -74.76

                    (-12.70)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -92.84

                    (0.80)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 38.92

                  • 1.48

                  • Asset Turnover

                  • 0.19

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -35.58M
                  Operating Margin
                  -393.52
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -9.99
                  Ownership

                  Institutional Ownership

                  39.31%

                  Top 10 Institutions

                  31.42%

                  Mutual Fund Ownership

                  25.57%

                  Float

                  78.78%

                  5% / Insider Ownership

                  2.99%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Growth Company Fund

                  •  

                    5,283,050

                  • 0.00

                  • 5.67

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    4,159,887

                  • 0.00

                  • 4.47

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,547,136

                  • 6.01

                  • 1.66

                  • Fidelity Advisor® Growth Opportunities

                  •  

                    1,354,187

                  • 0.00

                  • 1.45

                  • Fidelity® Series Growth Company Fund

                  •  

                    1,298,100

                  • 0.00

                  • 1.39

                  • iShares Russell 2000 (AU)

                  •  

                    1,241,688

                  • -1.46

                  • 1.35

                  • iShares Nasdaq Biotechnology

                  •  

                    1,204,590

                  • -0.47

                  • 1.31

                  • Vanguard Extended Market Index Fund

                  •  

                    994,704

                  • 0.52

                  • 1.07

                  • Satuit Capital US Emerging Companies Fd

                  •  

                    758,000

                  • 0.00

                  • 0.81

                  • Candriam Eqs L Biotechnology

                  •  

                    725,000

                  • 0.00

                  • 0.78

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    13,737,152

                  • +9.94%

                  • 14.76

                  • BlackRock Fund Advisors

                  •  

                    3,139,538

                  • +1.52%

                  • 3.37

                  • Vanguard Group, Inc.

                  •  

                    2,891,306

                  • +5.91%

                  • 3.11

                  • Deerfield Management Co

                  •  

                    2,805,972

                  • +6.73%

                  • 3.01

                  • WCM Investment Management

                  •  

                    1,908,793

                  • -1.93%

                  • 2.05

                  • State Street Corp

                  •  

                    1,297,298

                  • -0.92%

                  • 1.39

                  • Northern Trust Investments, N.A.

                  •  

                    994,250

                  • -2.83%

                  • 1.07

                  • Satuit Capital Management, LLC

                  •  

                    758,000

                  • 0.00%

                  • 0.81

                  • Candriam Luxembourg

                  •  

                    725,000

                  • 0.00%

                  • 0.78

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Immunomedics Inc was incorporated in Delaware in 1982. It is a biopharmaceutical company which develops monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It has developed ...moreadvanced proprietary technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or ‘naked’ form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create targeted agents. Using these technologies, it has built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. Its product candidate, epratuzumab, is currently in two Phase III clinical trials in lupus. In oncology, the Company is planning to launch a Phase III pivotal trial for clivatuzuma...moreb labeled with a radioisotope in pancreatic cancer patients. Other solid tumor therapeutics in Phase II clinical development includes 2 antibody-drug conjugates; labetuzumab-SN-38 (IMMU-130) and hRS7-SN-38 (IMMU-132).It also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a DOCK-AND-LOCK™ (DNL™) method with for making fusion proteins and multifunctional antibodies. DNL™ is being used particularly to make bispecific antibodies targeting cancers and infectious diseases as a T-cell redirecting immunotherapy, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies. It has licensed its product candidate, epratuzumab, to UCB S.A., or UCB, for the treatment of all non-cancer indications worldwide. Epratuzumab’s advanced clinical testing is for the treatment of systemic lupus erythematosus, or SLE (lupus), in non-Hodgkin lymphoma, or NHL and acute lymphoblastic leukemia, or ALL. During the 2013 fiscal year, it have completed a Phase Ib clinical trial evaluating clivatuzumab tetraxetan (hPAM4) labeled with yttrium-90, or Y-90, with and without low-dose gemcitabine, in pancreatic cancer patients who had received at least 2 prior therapies. It also initiated a randomized Phase Ib study examining the Y-90-labeled clivatuzumab tetraxetan, with and without low-dose gemcitabine, in pancreatic cancer patients who have received at least 2 prior therapies. It is also conducting a National Cancer Institute, or NCI, grant-supported study combining unlabeled veltuzumab with Y-90-labeled epratuzumab tetraxetan in patients with diffuse large B-cell lymphoma, or DLBCL, the aggressive form of NHL. The second ADC in its product pipeline is, labetuzumab-SN-38, which is in a Phase I/II trial in patients with advanced colorectal cancer. In the first half of fiscal 2013, it plan to begin a new study examining the safety and tolerability of its third ADC, hRS7-SN-38, in patients with solid cancers, for which an Investigational New Drug (IND) application has been filed with the Food and Drug Administration (FDA). The Company competes with Biogen Idec, Roche, GlaxoSmithKline, Seattle Genetics, Merck Serono, Genmab, Amgen, Bristol-Myers Squibb, Bayer Healthcare Pharmaceuticals, Pfizer, AstraZeneca and Eli Lilly are engaged in the development of therapeutic autoimmune and oncology products. Its research and development activities, including testing in laboratory animals and in humans, its manufacture of antibodies, as well as the handling, labeling and storage of the product candidates that the company is developing, are all subject to stringent regulation, by the FDA in the U.S. and by comparable authorities in other countries.lessless

                  Key People

                  Ms. Cynthia L. Sullivan

                  CEO/Director/President

                  Dr. David M. Goldenberg,M.D.

                  Chairman of the Board/Chief Medical Officer/Chief Scientific Officer/Director/Founder

                  Mr. Peter P. Pfreundschuh

                  CFO/Chief Accounting Officer/Vice President, Divisional

                  Mr. Brian A. Markison

                  Director

                  Ms. Mary E. Paetzold

                  Director

                  • Immunomedics Inc

                  • 300 The American Road

                  • Morris Plains, NJ 07950

                  • USA.Map

                  • Phone: +1 973 605-8200

                  • Fax: +1 973 605-8282

                  • immunomedics.com

                  Incorporated

                  1982

                  Employees

                  120

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: